BAYER CROPSCIENCE BUYS BIOCONTROL COMPANY PROPHYTA (ENGLISH)

     (The following press release from Bayer AG was received by e-mail. It was 
not confirmed by the sender.) 
Dear Newsletter Subscriber, 
The following news item has been released: 
Further milestone to becoming a leading provider of integrated crop
solutions:
Bayer CropScience acquires Germany-based biocontrol company Prophyta GmbH 
Monheim, January 8, 2013 - Bayer CropScience has signed an agreement to
acquire Prophyta GmbH, a leading supplier of microbial crop protection
products headquartered in Malchow on the island of Poel in
Mecklenburg-Vorpommern, Germany, along with the company´s R&D laboratories
and its state-of-the-art production and formulation facilities in Wismar,
Germany. The acquisition further complements Bayer CropScience´s portfolio
and will help the company build a leading offer of integrated crop
solutions based on high-value seeds, innovative crop protection solutions
and customized services. Closing is expected within a few weeks. Financial
details were not disclosed. 
"This acquisition not only further strengthens our successful fruits and
vegetables business," said Dr. Rüdiger Scheitza, Member of the Board of
Management of Bayer CropScience AG and Head of Strategy & Business
Management. "Prophyta´s patented solid-state fermentation technology and
strong expertise in the formulation of live fungal spores will also help us
bringing new, innovative solutions to market." Prophyta will expand Bayer
CropScience´s existing biological pest control portfolio and allow the
company to further leverage its technology platform acquired through
Athenix Corporation and AgraQuest. 
"We are proud to become part of Bayer CropScience," commented Prophyta
Managing Director Dr. Peter Lüth. "Our comprehensive production and
formulation capacities will help Bayer CropScience to supply its worldwide
customers with large quantities of biologics based on natural fungal
micro-organisms." This acquisition also opens up many opportunities for
innovation in the area of Research & Development as well as growth within
the Bayer CropScience Marketing & Sales network. 
Prophyta, founded in 1992, offers customers well-established products
primarily based on biological control agents which are registered in more
than 30 countries worldwide. Key brands are Contans™ for control of
Sclerotinia and the nematicide BioAct ™. Furthermore, Prophyta has
developed a unique solid-state fermentation technology for production and
bioprocess development of filamentous fungi. Using this patented
technology, large quantities of fungal biomass as well as fungal spores can
be produced under axenic conditions. Prophyta employs a total staff of
approximately 30 full-time employees. 
About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health
care, agriculture and high-tech materials. Bayer CropScience, the subgroup
of Bayer AG responsible for the agricultural business, has annual sales of
EUR 7.255 billion (2011) and is one of the world’s leading innovative crop
science companies in the areas of seeds, crop protection and
non-agricultural pest control. The company offers an outstanding range of
products including high value seeds, innovative crop protection solutions
based on chemical and biological modes of action as well as an extensive
service backup for modern, sustainable agriculture. In the area of
non-agricultural applications, Bayer CropScience has a broad portfolio of
products and services to control pests from home and garden to forestry
applications. The company has a global workforce of 21,000 and is
represented in more than 120 countries. This and further news is available
at: http://www.press.bayercropscience.com. 
Find more information at http://www.bayercropscience.com. 
Forward-Looking Statements
This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. These factors include those discussed in Bayer’s public reports
which are available on the Bayer website at http://www.bayer.com. The
company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments. 
This press release is available here:
http://www.baynews.bayer.de/baynews/baynews.nsf/id/2013-0015-e 
Yours BayNews Editorial Team 
Bayer AG
Communications
Building W11
51368 Leverkusen, Germany 
--------------------------------------------------- 
Further news releases you can find here: http://www.press.bayer.com 
N.B. This is an automatically generated e-mail which you cannot reply to.
If you have any questions, please send us an e-mail via our contact form:
https://secure.bayer.com/bayer/contact.aspx?lang=en 
--------------------------------------------------- 
© Bayer AG, 51368 Leverkusen, Germany. 
All rights reserved. The entire contents, including images, graphics,
animations etc., of this e-mail and the server http://www.bayer.com are
copyrighted. 
Board of Management: Marijn Dekkers, Chairman | Werner Baumann, Wolfgang
Plischke, Richard Pott
Chairman of the Supervisory Board: Werner Wenning
Registered office: Leverkusen | Local Court  of Cologne, HRB 48248
 
 
Press spacebar to pause and continue. Press esc to stop.